Navigation Links
Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
Date:3/19/2008

re the property of their respective owners and are not the property of CollaGenex Pharmaceuticals, Inc. or any of our subsidiaries.

For further information:

Tender Offer Information

Innisfree M&A Incorporated

Shareholders: (in the US and Canada only) +1-877-800-5185

Banks, Brokers and Shareholders located outside the US and

Canada: +1-212-750-5834


'/>"/>
SOURCE Galderma Pharma S.A.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
2. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
3. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
4. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
5. The Pennsylvania Breast Cancer Coalition Announces Event at the University of Pennsylvania Hospital to Celebrate the 2008 Income Tax Check-Off Campaign
6. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
7. PRA International Announces New Office Opening in Mumbai
8. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
9. Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments
10. Forest Laboratories Announces Resignation of Ivan Gergel, MD
11. National Parkinson Foundation Announces Its New President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 2Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 3Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 4Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 2Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 3Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 4Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 5Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 6Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 7Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 8Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 9FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 1Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 2Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 3Clarient Reports Second Quarter Revenue Up 40 Percent 53673 1Clarient Reports Second Quarter Revenue Up 40 Percent 53673 2Clarient Reports Second Quarter Revenue Up 40 Percent 53673 3Clarient Reports Second Quarter Revenue Up 40 Percent 53673 4Clarient Reports Second Quarter Revenue Up 40 Percent 53673 5Clarient Reports Second Quarter Revenue Up 40 Percent 53673 6Clarient Reports Second Quarter Revenue Up 40 Percent 53673 7Clarient Reports Second Quarter Revenue Up 40 Percent 53673 8Clarient Reports Second Quarter Revenue Up 40 Percent 53673 9Clarient Reports Second Quarter Revenue Up 40 Percent 53673 10Cambrex Reports Second Quarter 2009 Results 53671 1Cambrex Reports Second Quarter 2009 Results 53671 2Cambrex Reports Second Quarter 2009 Results 53671 3Cambrex Reports Second Quarter 2009 Results 53671 4Cambrex Reports Second Quarter 2009 Results 53671 5Cambrex Reports Second Quarter 2009 Results 53671 6Cambrex Reports Second Quarter 2009 Results 53671 7Cambrex Reports Second Quarter 2009 Results 53671 8Cambrex Reports Second Quarter 2009 Results 53671 9Cambrex Reports Second Quarter 2009 Results 53671 10Cambrex Reports Second Quarter 2009 Results 53671 11Cambrex Reports Second Quarter 2009 Results 53671 12